Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma. Patients in relapse after first-, second-, or third-line therapy received 40 mg m-2 intravenous (i.v.) cisplatin, 1000 mg m -2 i.v. gemcitabine, and 2500 mg m-2 i.v. treosulfan on days 1 and 8. Cisplatin, gemcitabine, and treosulfan therapy was repeated every 5 weeks until progression of disease occurred. A maximum of 11 CGT cycles (mean, two cycles) was administered per patient. Four patients (4%) showed a partial response; 15 (17%) patients had stable disease; and 72 (79%) patients progressed upon first re-evaluation. Overall survival of all 91 patients was 6 months (2-year survival rate, 7%). Patients with partial remission or stable disease exhibited a median overall survival of 11 months (2-year survival rate, 36%), while patients with disease progression upon first re-evaluation had a median overall survival of 5 months (2-year survival rate, 0%). Treatment with CGT was efficient in one-fifth of the pretreated relapsed stage IV melanoma patients achieving disease stabilisation or partial remission with prolonged but limited survival. © 2007 Cancer Research UK.

Cite

CITATION STYLE

APA

Atzpodien, J., Terfloth, K., Fluck, M., & Reitz, M. (2007). Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. British Journal of Cancer, 97(10), 1329–1332. https://doi.org/10.1038/sj.bjc.6604045

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free